Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Committee To Hold Meeting On Genetic Test For Opioid Use Disorder

Executive Summary

The FDA will discuss the de novo request for opioid use disorder genetic test, AvertD.

You may also be interested in...

FDA Panel Recommends Against De Novo Classification For Genetic OUD Risk Test

The FDA Clinical Chemistry and Toxicology Devices Panel voted 11-2 that the risks of AvertD’s genetic test for opioid use disorder outweigh the product’s potential benefits as a diagnostic. 

FDA Guidance On Substance Use Disorder Supports Medical Device Innovation

In a 30 August guidance from the US FDA, the agency proposed support and guidance for medical device innovation to treat substance use disorder.

FDA Finalizes De Novo Process, Updates Related Guidance Docs

The pathway is used to clear class I and II products that don’t have a predicate device, including many innovative technologies. The original draft rule came out in 2018.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts